Fulgent Genetics Inc (FLGT)

Financial leverage ratio

Dec 31, 2024 Sep 30, 2024 Jun 30, 2024 Mar 31, 2024 Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020
Total assets US$ in thousands 1,219,960 1,233,760 1,232,240 1,229,880 1,273,110 1,358,400 1,354,580 1,376,770 1,386,050 1,405,780 1,461,660 1,465,590 1,278,720 1,204,670 1,049,860 999,083 700,461 247,311 95,915 89,325
Total stockholders’ equity US$ in thousands 1,133,230 1,138,440 1,132,550 1,129,940 1,136,100 1,258,700 1,259,760 1,268,920 1,269,880 1,281,400 1,304,760 1,312,960 1,165,880 1,036,780 920,725 801,566 569,387 186,955 87,043 81,372
Financial leverage ratio 1.08 1.08 1.09 1.09 1.12 1.08 1.08 1.08 1.09 1.10 1.12 1.12 1.10 1.16 1.14 1.25 1.23 1.32 1.10 1.10

December 31, 2024 calculation

Financial leverage ratio = Total assets ÷ Total stockholders’ equity
= $1,219,960K ÷ $1,133,230K
= 1.08

The financial leverage ratio of Fulgent Genetics Inc over the period from March 31, 2020, to December 31, 2024, has remained relatively stable, varying between 1.08 and 1.32. This ratio reflects the company's reliance on debt financing to support its operations and growth initiatives.

The trend indicates that Fulgent Genetics has been maintaining a conservative level of financial leverage, with the ratio generally staying close to the 1.10 to 1.15 range. This suggests that the company has a balanced approach to using debt to fund its activities while also maintaining a healthy equity base.

Overall, the consistent financial leverage ratio implies that Fulgent Genetics has been managing its debt levels effectively, indicating a prudent financial strategy that balances the benefits of leverage with the risks associated with higher debt obligations.


Peer comparison

Dec 31, 2024